Boertien WE - Search Results

1

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.

Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT. Zittema D, et al. Among authors: boertien we. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1553-62. doi: 10.2215/CJN.08690813. Epub 2014 Jul 3. Clin J Am Soc Nephrol. 2014. PMID: 24993447 Free PMC article.

2

Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.

Meijer E, Boertien WE, Zietse R, Gansevoort RT. Meijer E, et al. Among authors: boertien we. Kidney Blood Press Res. 2011;34(4):235-44. doi: 10.1159/000326902. Epub 2011 Jun 21. Kidney Blood Press Res. 2011. PMID: 21691126 Review.

3

Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease.

Spithoven EM, Meijer E, Borns C, Boertien WE, Gaillard CA, Kappert P, Greuter MJ, van der Jagt E, Vart P, de Jong PE, Gansevoort RT. Spithoven EM, et al. Among authors: boertien we. Eur Radiol. 2016 Mar;26(3):683-92. doi: 10.1007/s00330-015-3877-y. Epub 2015 Jul 11. Eur Radiol. 2016. PMID: 26162576 Free PMC article.

4

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.

Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT. Meijer E, et al. Among authors: boertien we. Am J Kidney Dis. 2010 Nov;56(5):883-95. doi: 10.1053/j.ajkd.2010.06.023. Am J Kidney Dis. 2010. PMID: 20888104

5

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.

Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT. Zittema D, et al. Among authors: boertien we. Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111. Epub 2012 Apr 19. Clin J Am Soc Nephrol. 2012. PMID: 22516290

6

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.

Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT. Boertien WE, et al. Nephrol Dial Transplant. 2012 Nov;27(11):4131-7. doi: 10.1093/ndt/gfs070. Epub 2012 Apr 20. Nephrol Dial Transplant. 2012. PMID: 22523115

7

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP. Boertien WE, et al. Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038. Epub 2012 Oct 22. Am J Kidney Dis. 2013. PMID: 23089511 Free PMC article.

8

Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.

Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, Navis G, Gansevoort RT. Spithoven EM, et al. Among authors: boertien we. Am J Kidney Dis. 2013 Sep;62(3):531-40. doi: 10.1053/j.ajkd.2013.03.030. Epub 2013 May 25. Am J Kidney Dis. 2013. PMID: 23714171

9

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT. Boertien WE, et al. Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31. Kidney Int. 2013. PMID: 23903369 Free article. Clinical Trial.

10

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Boertien WE, et al. Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15. Am J Kidney Dis. 2015. PMID: 25600953

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters